Tafamidis treatment in transthyretin cardiac amyloidosis: A retrospective cohort analysis of outcomes and associated factors

Key Points

• Tafamidis treatment significantly improves outcomes in transthyretin cardiac amyloidosis patients, even with various associated factors.
• Key patient factors such as age and disease severity were evaluated across a cohort of 150 individuals over 5 years.
• Analysis of retrospective cohort data highlights the importance of close monitoring of treatment effects and individual variability.
• Findings suggest that personalized approaches could enhance treatment efficacy, though external validation is needed.